Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Non-cash Items: 2016-2025

Historic Non-cash Items for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $9.9 million.

  • Rocket Pharmaceuticals' Non-cash Items fell 90.51% to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year decrease of 90.51%. This contributed to the annual value of $63.3 million for FY2024, which is 74.74% down from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Non-cash Items stood at $9.9 million, which was up 53.98% from $6.5 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' Non-cash Items' 5-year high stood at $349.4 million during Q1 2021, with a 5-year trough of $6.5 million in Q2 2025.
  • Moreover, its 3-year median value for Non-cash Items was $104.7 million (2024), whereas its average is $105.0 million.
  • Per our database at Business Quant, Rocket Pharmaceuticals' Non-cash Items skyrocketed by 333.28% in 2021 and then plummeted by 95.27% in 2025.
  • Rocket Pharmaceuticals' Non-cash Items (Quarterly) stood at $128.8 million in 2021, then declined by 7.80% to $118.8 million in 2022, then soared by 111.00% to $250.6 million in 2023, then slumped by 74.74% to $63.3 million in 2024, then plummeted by 90.51% to $9.9 million in 2025.
  • Its last three reported values are $9.9 million in Q3 2025, $6.5 million for Q2 2025, and $30.7 million during Q1 2025.